Report Package: TCR-Based Antibody and T-Cell Immunotherapy

  • ID: 4564554
  • Report
  • 546 Pages
  • La Merie Publishing
1 of 2

T-Cell Receptor (TCR)-based therapeutic cells and recombinant antibodies or antibody fusion proteins have emerged as a new class of effective cancer therapeutics. Both treatment modalities have in common that they are directed to intracellular targets which are estimated to be 3-4 times more frequent than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody or chimeric antigen receptor (CAR) T-cell therapy. While TCR engineered T-cells exert their effector function via the cytotoxicity of T-cells, antibodies can act via their intrinsic effects (ADCC, CDC) or by enhancing them as antibody-drug conjugates or T-cell redirecting bispecific antibodies.

This report package includes two full reports covering TCR-based T-cell and recombinant antibody (fusion protein) immunotherapy of cancer.

The original reports were published in January and May 2018, respectively:

"Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends"

and

"TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals"

*Detailed report descriptions, tables of contents and sample pages from the reports can be found on the respective product pages, which can be found in the "Also available" Section below.

Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Note: Product cover images may vary from those shown
Adroll
adroll